KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Total Non-Current Liabilities (2017 - 2025)

Aquestive Therapeutics (AQST) has 8 years of Total Non-Current Liabilities data on record, last reported at $186.8 million in Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities rose 17.36% year-over-year to $186.8 million; the TTM value through Dec 2025 reached $186.8 million, up 17.36%, while the annual FY2025 figure was $186.8 million, 17.36% up from the prior year.
  • Total Non-Current Liabilities reached $186.8 million in Q4 2025 per AQST's latest filing, up from $165.6 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $186.8 million in Q4 2025 and bottomed at $112.0 million in Q1 2021.
  • Average Total Non-Current Liabilities over 5 years is $154.1 million, with a median of $159.8 million recorded in 2023.
  • Peak YoY movement for Total Non-Current Liabilities: skyrocketed 44.9% in 2021, then dropped 6.74% in 2023.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $141.6 million in 2021, then increased by 22.56% to $173.6 million in 2022, then dropped by 6.74% to $161.9 million in 2023, then dropped by 1.67% to $159.2 million in 2024, then grew by 17.36% to $186.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were $186.8 million in Q4 2025, $165.6 million in Q3 2025, and $164.2 million in Q2 2025.